New Triple-Threat treatment tested for Tough-to-Treat leukemia
NCT ID NCT06445959
Summary
This study is testing a combination of three drugs—decitabine, venetoclax, and olutasidenib—for adults with acute myeloid leukemia (AML) that has a specific genetic change called an IDH1 mutation. The first part aims to find a safe and effective dose. The second part will see how well this combination helps control the cancer in people with newly diagnosed or returning AML who cannot tolerate strong chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUTANT IDH1 INHIBITOR OLUTASIDENIB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.